Commercial DNA-analysing company 23andMe is looking to launch a new DNA assessment to help individuals discover their risk of developing type 2 diabetes. Several million customers will receive the information over the coming weeks.
Researchers at Cold Spring Harbor Laboratory have created a list of genetic “usual suspects” from a computational analysis of 635 datasets across around 27,000 genetic samples.
The eLife online journal has published its first “computationally reproducible” article, where figures are integrated with the software, data and computational environment required to produce them.
A neuron-optimised CRISPR-Cas9 activation system has been used by scientists to regulate genes in a rat brain for the first time. This technique could lead to researchers being able to probe genetic influences on brain health and disease in model organisms which more closely resemble humans.
New information from China has suggested that the twins recently created using CRISPR gene-editing technology to make them HIV-resistance could also develop genetically-enhanced brains.
Researchers from the Wake Forest Institute for Regenerative Medicine (WFIRM) have determined a new way to deliver DNA editing tools so that the presence of their proteins in cells is reduced, in what they have called a “hit and run” approach.
Global life science researcher Bio-Rad has announced that its droplet digital PCR-based test for chronic myeloid leukaemia (CML), the first of its kind, has been cleared by the FDA. The test quantifies BCR-ABL, the gene fusion which causes CML, in the blood.
TEXLab, a mathematical AI software created by scientists at Imperial College London and the University of Melbourne can predict survival rates of patients with ovarian cancer more accurately than any current method, a trial published in Nature Communications has found.
The leading advisor for the UK science and technology (S&T) sectors has estimated that despite Brexit, Cambridge and Oxford’s S&T companies will require 2.5 million more square feet of lab and research space over the next five years, and are looking to accommodate 20,000 new R&D workers by 2023.
Esketamine, a Johnson & Johnson antidepressant based on the party drug ketamine, has received backing from an FDA independent advisory group.
Toxic antibody tisutumab vedotin (TV) has shown promise as a treatment for a number of types of advanced cancer. This “trojan horse” approach has now reached the stage of being tested on a wider variety of patients. Institute of Cancer Research and Royal Marsden NHS Foundation Trust researchers tested the drug on 147 patients to evaluate potential benefits and side effects.
The Pistoia Alliance, a global not-for-profit company working in life sciences R&D, has announced the launch of the next phase in its ongoing blockchain project. The next phase includes a workshop on 12 March 2019 open to both members and non-members which will look to develop several potential use cases to the proof-of-concept stage. It will also identify which blockchain applications will have no industry value.
For the first time, scientists have changed human stem cells into functional insulin-producing cells in mice, potentially promising a breakthrough in treatment for those suffering from type 1 diabetes.
Oxford Nanopore has launched its two new “109” cDNA kits, which provide high throughput while generating complete sequences of full-length cDNA strands with a low input option of just 1ng PolyA+ RNA.